Switch theme
Sign up to access all valuation multiples
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
1999
21
LTM Revenue $2.5M
Last FY EBITDA -$2.7M
$20.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prolight Diagnostics has a last 12-month revenue (LTM) of $2.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prolight Diagnostics achieved revenue of n/a and an EBITDA of -$2.7M.
Prolight Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prolight Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $1.8M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$2.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.6M | XXX | -$2.9M | XXX | XXX | XXX |
| EBIT Margin | -65% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$2.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, Prolight Diagnostics's stock price is SEK 0 (or $0).
Prolight Diagnostics has current market cap of SEK 213M (or $22.5M), and EV of SEK 197M (or $20.9M).
See Prolight Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.9M | $22.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, Prolight Diagnostics has market cap of $22.5M and EV of $20.9M.
Prolight Diagnostics's trades at n/a EV/Revenue multiple, and -7.8x EV/EBITDA.
Equity research analysts estimate Prolight Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prolight Diagnostics's P/E ratio is not available.
See valuation multiples for Prolight Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22.5M | XXX | $22.5M | XXX | XXX | XXX |
| EV (current) | $20.9M | XXX | $20.9M | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.8x | XXX | XXX | XXX |
| EV/EBIT | -12.7x | XXX | -7.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProlight Diagnostics's last 12 month revenue growth is 282%
Prolight Diagnostics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
Prolight Diagnostics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prolight Diagnostics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prolight Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 282% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prolight Diagnostics acquired XXX companies to date.
Last acquisition by Prolight Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Prolight Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prolight Diagnostics founded? | Prolight Diagnostics was founded in 1999. |
| Where is Prolight Diagnostics headquartered? | Prolight Diagnostics is headquartered in Sweden. |
| How many employees does Prolight Diagnostics have? | As of today, Prolight Diagnostics has 21 employees. |
| Is Prolight Diagnostics publicy listed? | Yes, Prolight Diagnostics is a public company listed on NGM. |
| What is the stock symbol of Prolight Diagnostics? | Prolight Diagnostics trades under PRLD ticker. |
| When did Prolight Diagnostics go public? | Prolight Diagnostics went public in 2017. |
| Who are competitors of Prolight Diagnostics? | Similar companies to Prolight Diagnostics include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Prolight Diagnostics? | Prolight Diagnostics's current market cap is $22.5M |
| What is the current revenue of Prolight Diagnostics? | Prolight Diagnostics's last 12 months revenue is $2.5M. |
| What is the current revenue growth of Prolight Diagnostics? | Prolight Diagnostics revenue growth (NTM/LTM) is 282%. |
| What is the current EV/Revenue multiple of Prolight Diagnostics? | Current revenue multiple of Prolight Diagnostics is 8.2x. |
| Is Prolight Diagnostics profitable? | Yes, Prolight Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
